A
Alcista
Alcista · 25%ELVN
$25.90
Precio del escenario
$41.250
+2.718 (+6.59%)Al cierre
Loading chart…
- Máximo
- 41.365
- Apertura
- 38.860
- Precio medio ponderado por volumen
- 40.34
- Volumen
- 1.94M
- Capitalización
- 1.10B
- Mínimo
- 38.410
- Importe
- 78.19M
- EV/EBITDA, TTM
- 0.00
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
Análisis de IA of Enliven Therapeutics Inc (ELVN)
ComprarEnliven Therapeutics Inc is a good buy right now due to its strong cash reserves of $895.2 million, which ensures liquidity into 2030, and a current price of $37.32 significantly below analyst price targets ranging from $70 to $82. The main risk is the negative earnings trend, with an EPS of -0.49 reported last quarter, missing expectations by $0.10.
Métricas de valoración
El PER previsto actual de Enliven Therapeutics Inc (ELVN) es 0.00, frente a su media de 5 años de -9.29.
Escenarios de precio de Alphio AI para ELVN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ELVN en cartera
Cronología de eventos
Noticias
5.010-14PRnewswireEnliven Appoints New Board Member Ahead of Phase 3 Trial
9.010-06NewsfilterEnliven on Track to Initiate ENABLE-2 Trial by Year-End 2026
6.010-02CNBCLatest Ratings and Outlook from Wall Street
6.010-01CNBCLatest Wall Street Rating Updates
1.009-03PRnewswireEnliven Therapeutics Announces Upcoming Investor Conference Participation
Preguntas frecuentes sobre ELVN, respondidas por Alphio AI
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Enliven Therapeutics Inc is a good buy right now due to its strong cash reserves of $895.2 million, which ensures liquidity into 2030, and a current price of $37.32 significantly below analyst price targets ranging from $70 to $82. The main risk is the negative earnings trend, with an EPS of -0.49 reported last quarter, missing expectations by $0.10.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.